



**HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Austedo - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: <input type="checkbox"/> Medicare	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:
Strength:
Directions / SIG:

**Please attach any pertinent medical history including labs and information for this member that may support approval.
Please answer the following questions and sign.**

<p>Q1. Does the patient have the diagnosis of tardive dyskinesia? If No, go to 11.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q2. Has the patient been previously approved for treatment with Austedo? If No, go to 4.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q3. Does the member have a documented improvement in symptoms related to tardive dyskinesia with an updated abnormal involuntary movement scale (AIMS) with assessment attached? If Yes, go to 19.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q4. Is the patient 18 years of age or older?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q5. Is Austedo being prescribed by, or in consultation with, a neurologist or psychiatrist?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q6. Has a copy of the abnormal involuntary movement scale (AIMS) assessment been attached?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q7. Is there documentation that other movement disorders (such as Parkinson's disease, chorea associated with</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Austedo - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Huntington's disease) have been excluded?
Documentation must be attached.

Yes checkbox

No checkbox

Q8. Does the patient have a current or former chronic use of a dopamine antagonist (e.g., antipsychotic [first or second generation], metoclopramide, prochlorperazine, droperidol, promethazine, etc)?
Must attach documentation.

Yes checkbox

No checkbox

Q9. Have all potential contraindications (including congenital long QT syndrome, arrhythmias associated with prolonged QT interval) been excluded?

Yes checkbox

No checkbox

Q10. Will the patient be treated concurrently with a monoamine oxidase (MAO) inhibitor?
If Yes, go to 19.

Yes checkbox

No checkbox

Q11. Does the patient have the diagnosis of chorea associated with Huntington's disease?

Yes checkbox

No checkbox

Q12. Has the patient been previously approved for treatment with Austedo?

Yes checkbox

No checkbox

Q13. Does the member have a documented improvement in symptoms of chorea with medical records attached?
Must attach documentation.
If Yes, go to 19.

Yes checkbox

No checkbox

Q14. Is the patient 18 years of age or older?

Yes checkbox

No checkbox

Q15. Is Austedo being prescribed by or in consultation with a neurologist or psychiatrist?

Yes checkbox

No checkbox

Q16. Have other movement disorders (such as Parkinson's disease, tardive dyskinesia) been excluded with documentation attached?

Yes checkbox

No checkbox

Q17. Have all potential contraindications (including congenital long QT syndrome, arrhythmias associated with prolonged QT interval) been excluded?

Yes checkbox

No checkbox

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Austedo - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Q18. Will the patient be treated concurrently with a monoamine oxidase (MAO) inhibitor?

Yes

No

Q19. Additional Information:

Q20. Requested Duration:

12 Months

Prescriber Signature

Date

2021 Medicare Prior Authorization Request